UNITED LAB(03933)
16.500+0.900+5.77%
Market data delayed 15 minutes
Login to post
- CommunityCommunity
- NewsNews
- ProfileProfile
- AnnouncementsAnnouncements
No Content- United Laboratories International Unit's Antibiotic Passes Quality, Efficacy Consistency EvaluationUnited Laboratories International Unit's Antibiotic Passes Quality, Efficacy Consistency Evaluation
MT Newswires Live · 03-10
- United Laboratories Unit's Chronic Kidney Disease Drug Gets US Clinical Trial ApprovalUnited Laboratories Unit's Chronic Kidney Disease Drug Gets US Clinical Trial Approval
MT Newswires Live · 03-04
- BRIEF-United Laboratories International Says US FDA Approved UBT251 Injection For Phase II Clinical TrialBRIEF-United Laboratories International Says US FDA Approved UBT251 Injection For Phase II Clinical Trial
Reuters · 03-03
- United Laboratories International - Ubt251 Injection Approved for Phase Ii Clinical Trial by U.S. Food and Drug AdministrationUnited Laboratories International - Ubt251 Injection Approved for Phase Ii Clinical Trial by U.S. Food and Drug Administration
THOMSON REUTERS · 03-03
- Is The United Laboratories International Holdings Limited's (HKG:3933) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Simply Wall St. · 02-27
Is The United Laboratories International Holdings Limited's (HKG:3933) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - UOB Kay Hian Downgrades The United Laboratories International Holdings to Hold from Buy; Price Target is HK$13UOB Kay Hian Downgrades The United Laboratories International Holdings to Hold from Buy; Price Target is HK$13
MT Newswires Live · 02-14
- Benign Growth For The United Laboratories International Holdings Limited (HKG:3933) Underpins Its Share Price
Simply Wall St. · 02-05
Benign Growth For The United Laboratories International Holdings Limited (HKG:3933) Underpins Its Share Price - The United Laboratories International Unit Gets Clinical Trial Nod for Chronic Kidney Disease DrugThe United Laboratories International Unit Gets Clinical Trial Nod for Chronic Kidney Disease Drug
MT Newswires Live · 01-23
- BRIEF-United Laboratories International Announces Approval For Clinical Trial Of UBT251 InjectionBRIEF-United Laboratories International Announces Approval For Clinical Trial Of UBT251 Injection
Reuters · 01-22
- United Laboratories International - Approval for Clinical Trial of Ubt251 Injection on Indication of Chronic Kidney Disease by NmpaUnited Laboratories International - Approval for Clinical Trial of Ubt251 Injection on Indication of Chronic Kidney Disease by Nmpa
THOMSON REUTERS · 01-22
- Here's Why We Think United Laboratories International Holdings (HKG:3933) Is Well Worth Watching
Simply Wall St. · 01-10
Here's Why We Think United Laboratories International Holdings (HKG:3933) Is Well Worth Watching - Private companies are The United Laboratories International Holdings Limited's (HKG:3933) biggest owners and were hit after market cap dropped HK$1.2b
Simply Wall St. · 2024-12-19
Private companies are The United Laboratories International Holdings Limited's (HKG:3933) biggest owners and were hit after market cap dropped HK$1.2b - BRIEF-United Laboratories International Says Mupirocin Ointment Submitted By Unit Approved By NMPABRIEF-United Laboratories International Says Mupirocin Ointment Submitted By Unit Approved By NMPA
Reuters · 2024-12-04
- United Laboratories International - Mupirocin Ointment Submitted by Unit Has Been Approved by NmpaUnited Laboratories International - Mupirocin Ointment Submitted by Unit Has Been Approved by Nmpa
THOMSON REUTERS · 2024-12-04
- Are Robust Financials Driving The Recent Rally In The United Laboratories International Holdings Limited's (HKG:3933) Stock?
Simply Wall St. · 2024-11-28
Are Robust Financials Driving The Recent Rally In The United Laboratories International Holdings Limited's (HKG:3933) Stock? - The United Laboratories International Issues Over 3.6 Million Shares Under Share Award SchemeThe United Laboratories International Issues Over 3.6 Million Shares Under Share Award Scheme
MT Newswires Live · 2024-11-15
- United Laboratories International - Group's Product Cefuroxime Sodium for Injection Passed Consistency Evaluation by NmpaUnited Laboratories International - Group's Product Cefuroxime Sodium for Injection Passed Consistency Evaluation by Nmpa
THOMSON REUTERS · 2024-11-14
- These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely
Simply Wall St. · 2024-11-11
These 4 Measures Indicate That United Laboratories International Holdings (HKG:3933) Is Using Debt Safely - United Laboratories International Unit's Antibiotic Drug Passes Chinese Regulator's Consistency EvaluationUnited Laboratories International Unit's Antibiotic Drug Passes Chinese Regulator's Consistency Evaluation
MT Newswires Live · 2024-10-28
- BRIEF-United Laboratories International Says Ceftazidime For Injection Passed Consistency Evaluation By NMPABRIEF-United Laboratories International Says Ceftazidime For Injection Passed Consistency Evaluation By NMPA
Reuters · 2024-10-25
Company Profile
Company NameUNITED LABMarketSEHKEstablishment Date1990Employees15000Office Location6 Fuk Wang Street,Yuen Long Industrial Estate,Yuen Long,New Territories,Hong KongWebsiteZip Code- -PhoneFax852 2687 1031IntroductionThe United Laboratories International Holdings Limited is an investment holding company principally engaged in the sales of intermediate products, bulk medicine and finished products. The Company operates its business through three segments. The Intermediate Products segment is engaged in the sale of intermediate products. The Bulk Medicine segment is engaged in the sale of bulk medicine. The Finished Products segment is engaged in the sale of antibiotics finished products, non-antibiotics finished products and capsule casings. Through its subsidiaries, the Company is also engaged in the production and sale of organic fertilizer.Industry
PharmaceuticalsIPO Information
Listing Date- -Issue Price- -
- 1D
- 5D
- Day
- Week
- Month
High
16.960
Open
15.420
Volume%
1.78
Low
15.340
Close
15.600
T/O Rate
1.01%
抱歉，当前请求异常(-1)
Terms and Conditions·Privacy Policy
Company: TTMF Limited. Tech supported by Xiangshang Yixin.
Email：uservice@ttm.financial